EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthesis, Anticancer Evaluation, and Molecular Docking of Novel Thiazolobenzimidazole–Thiazole Hybrids as Potent Colon Cancer Inhibitors

Bader Huwaimel, Amr S Abouzied, Magdi E A Zaki iD, Abdulwahab Alamri, Basant Farag, Saad Alqarni, Sobhi M Gomha iD

ChemistryOpen · 2025

DOI: 10.1002/open.202500288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistryOpen, 2025. Verfasst von Bader Huwaimel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, 55473, Saudi Arabia. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Antineoplastic Agents, Thiazoles, Colonic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Deanship at University of Ha'il - Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, a series of novel benzimidazothiazole–thiazole hybrids is synthesized via the condensation of 2‐(1‐(3‐methylbenzoimidazo[2,1‐b]thiazol‐2‐yl)ethylidene)hydrazine‐1‐carbothioamide with various hydrazonoyl halides and α‐halo compounds. Structural elucidation is confirmed by infrared, nuclear magnetic resonance (NMR), mass spectrometry (MS), and elemental analysis. The anticancer activities of the synthesized compounds are assessed against the HCT‐116 colon carcinoma cell line using the MTT assay, where compound 16b exhibits the strongest cytotoxic effect (IC 50 = 4.31 ± 1.07 μM), outperforming the reference drug doxorubicin (IC 50 = 7.05 ± 0.49 μM). Compounds 16a , 12 , and 10a also demonstrate potent activity (IC 50 < 7.1 μM). Molecular docking studies against the colon cancer protein target 6MTU reveal that these active compounds, especially 16b , form stable interactions through key hydrogen bonding and π‐type interactions, with binding energies more favorable than doxorubicin. Additionally, in silico ADMET analysis highlights excellent absorption (up to 100%), moderate distribution, CYP450 interactions, and no predicted skin sensitization toxicity. These results position compound 16b as a promising lead molecule for further preclinical development as a targeted colon cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Docking SimulationAntineoplastic AgentsThiazolesColonic NeoplasmsBenzimidazolesHumansDrug Screening Assays, AntitumorHCT116 CellsCell ProliferationStructure-Activity RelationshipMolecular Structure

Stichwörter der Autor:innen

ADMET profiling.HCT‐116anticancer activitybenzimidazothiazoleshydrazonoyl chloridesmolecular dockingthiazoles

Substanzen

Antineoplastic AgentsThiazolesBenzimidazoles

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, University of Ha'il, Ha'il, 55473, Saudi Arabia.
  • Medical and Diagnostic Research Center, University of Ha'il, Ha'il, 55473, Saudi Arabia.
  • Department of Chemistry, Faculty of Science, Imam Mohammed Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia.
  • Department of Pharmacology and Toxicology, College of Pharmacy, University of Ha'il, Ha'il, 55211, Saudi Arabia.
  • Department of Chemistry, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt.
  • Department of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah, 42351, Saudi Arabia.

ORCID-Profile: Magdi E A Zaki, Sobhi M Gomha

Förderung

  • Scientific Research Deanship at University of Ha'il - Saudi Arabia

Zitieren

APA

Huwaimel, B., Abouzied, A. S., Zaki, M. E. A., Alamri, A., Farag, B., Alqarni, S., & Gomha, S. M. (2025). Synthesis, Anticancer Evaluation, and Molecular Docking of Novel Thiazolobenzimidazole–Thiazole Hybrids as Potent Colon Cancer Inhibitors. ChemistryOpen. https://doi.org/10.1002/open.202500288

Vancouver

Huwaimel B, Abouzied AS, Zaki MEA, Alamri A, Farag B, Alqarni S, et al. Synthesis, Anticancer Evaluation, and Molecular Docking of Novel Thiazolobenzimidazole–Thiazole Hybrids as Potent Colon Cancer Inhibitors. ChemistryOpen. 2025. doi:10.1002/open.202500288

BibTeX
@article{Huwaimel2025,
  author = {Huwaimel, Bader and Abouzied, Amr S and Zaki, Magdi E A and Alamri, Abdulwahab and Farag, Basant and Alqarni, Saad and Gomha, Sobhi M},
  title = {Synthesis, Anticancer Evaluation, and Molecular Docking of Novel Thiazolobenzimidazole–Thiazole Hybrids as Potent Colon Cancer Inhibitors},
  journal = {ChemistryOpen},
  year = {2025},
  doi = {10.1002/open.202500288}
}
Kostenlos starten →